108 related articles for article (PubMed ID: 9616287)
1. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.
Dørum A; Møller P; Kamsteeg EJ; Scheffer H; Burton M; Heimdal KR; Maehle LO; Hovig E; Tropé CG; van der Hout AH; van der Meulen MA; Buys CH; te Meerman GJ
Eur J Cancer; 1997 Dec; 33(14):2390-2. PubMed ID: 9616287
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
[TBL] [Abstract][Full Text] [Related]
3. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Sarantaus L; Huusko P; Eerola H; Launonen V; Vehmanen P; Rapakko K; Gillanders E; Syrjäkoski K; Kainu T; Vahteristo P; Krahe R; Pääkkönen K; Hartikainen J; Blomqvist C; Löppönen T; Holli K; Ryynänen M; Bützow R; Borg A; Wasteson Arver B; Holmberg E; Mannermaa A; Kere J; Kallioniemi OP; Winqvist R; Nevanlinna H
Eur J Hum Genet; 2000 Oct; 8(10):757-63. PubMed ID: 11039575
[TBL] [Abstract][Full Text] [Related]
4. Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.
Dørum A; Hovig E; Tropé C; Inganas M; Møller P
Eur J Cancer; 1999 May; 35(5):779-81. PubMed ID: 10505039
[TBL] [Abstract][Full Text] [Related]
5. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
[TBL] [Abstract][Full Text] [Related]
6. Genetic epidemiology of BRCA1 mutations in Norway.
Møller P; Heimdal K; Apold J; Fredriksen A; Borg A; Hovig E; Hagen A; Hagen B; Pedersen JC; Maehle L; ;
Eur J Cancer; 2001 Dec; 37(18):2428-34. PubMed ID: 11720839
[TBL] [Abstract][Full Text] [Related]
7. Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.
Dørum A; Heimdal K; Hovig E; Inganäs M; Møller P
Am J Hum Genet; 1999 Sep; 65(3):671-9. PubMed ID: 10441573
[TBL] [Abstract][Full Text] [Related]
8. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.
Infante M; Durán M; Acedo A; Pérez-Cabornero L; Sanz DJ; García-González M; Beristain E; Esteban-Cardeñosa E; de la Hoya M; Teulé A; Vega A; Tejada MI; Lastra E; Miner C; Velasco EA
Clin Genet; 2010 Jan; 77(1):60-9. PubMed ID: 19912264
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
Muller D; Bonaiti-Pellié C; Abecassis J; Stoppa-Lyonnet D; Fricker JP
Fam Cancer; 2004; 3(1):15-20. PubMed ID: 15131401
[TBL] [Abstract][Full Text] [Related]
11. Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
Pertesi M; Konstantopoulou I; Yannoukakos D
Clin Genet; 2011 Oct; 80(4):375-82. PubMed ID: 20840220
[TBL] [Abstract][Full Text] [Related]
12. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.
Peelen T; van Vliet M; Petrij-Bosch A; Mieremet R; Szabo C; van den Ouweland AM; Hogervorst F; Brohet R; Ligtenberg MJ; Teugels E; van der Luijt R; van der Hout AH; Gille JJ; Pals G; Jedema I; Olmer R; van Leeuwen I; Newman B; Plandsoen M; van der Est M; Brink G; Hageman S; Arts PJ; Bakker MM; Devilee P
Am J Hum Genet; 1997 May; 60(5):1041-9. PubMed ID: 9150151
[TBL] [Abstract][Full Text] [Related]
13. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation.
Apostolou P; Pertesi M; Aleporou-Marinou V; Dimitrakakis C; Papadimitriou C; Razis E; Christodoulou C; Fountzilas G; Yannoukakos D; Konstantopoulou I; Fostira F
Clin Genet; 2017 Mar; 91(3):482-487. PubMed ID: 27357818
[TBL] [Abstract][Full Text] [Related]
14. Evidence of a founder BRCA1 mutation in Scotland.
Liede A; Cohen B; Black DM; Davidson RH; Renwick A; Hoodfar E; Olopade OI; Micek M; Anderson V; De Mey R; Fordyce A; Warner E; Dann JL; King MC; Weber B; Narod SA; Steel CM
Br J Cancer; 2000 Feb; 82(3):705-11. PubMed ID: 10682686
[TBL] [Abstract][Full Text] [Related]
15. Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
Hadjisavvas A; Charalambous E; Adamou A; Neuhausen SL; Christodoulou CG; Kyriacou K
Cancer Genet Cytogenet; 2004 Jun; 151(2):152-6. PubMed ID: 15172753
[TBL] [Abstract][Full Text] [Related]
16. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
Heimdal K; Maehle L; Apold J; Pedersen JC; Møller P
Eur J Cancer; 2003 Oct; 39(15):2205-13. PubMed ID: 14522380
[TBL] [Abstract][Full Text] [Related]
17. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
Papi L; Putignano AL; Congregati C; Zanna I; Sera F; Morrone D; Falchetti M; Turco MR; Ottini L; Palli D; Genuardi M
Breast Cancer Res Treat; 2009 Oct; 117(3):497-504. PubMed ID: 18821011
[TBL] [Abstract][Full Text] [Related]
18. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations.
Rudkin TM; Hamel N; Galvez M; Hogervorst F; Gille JJ; Møller P; Apold J; Foulkes WD
BMC Med Genet; 2006 Mar; 7():15. PubMed ID: 16509964
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families.
Díez O; Cortés J; Domènech M; Brunet J; Del Río E; Pericay C; Sanz J; Alonso C; Baiget M
Int J Cancer; 1999 Nov; 83(4):465-9. PubMed ID: 10508480
[TBL] [Abstract][Full Text] [Related]
20. Identification of a founder BRCA2 mutation in Sardinian breast cancer families.
Monne M; Piras G; Fancello P; Santona MC; Uras A; Landriscina G; Mastio G; Gabbas A
Fam Cancer; 2007; 6(1):73-9. PubMed ID: 17216544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
